Dollar General Shines Through Challenging Times

June 5, 2012

The dollar store giant reported another strong quarter and could issue 25 million new shares in a secondary offering. We think the shares are fairly valued.

Starbucks Buys a…Bakery?

June 5, 2012

Starbucks hopes to add afternoon food items to drive more revenue and store traffic. We take a brief look at the La Boulange acquisition.

Salesforce.com Adds Some Social Firepower

June 4, 2012

Salesforce.com has acquired social media company Buddy Media. Only time will tell if the deal is worthwhile, but we still view Salesforce.com’s shares as fairly valued.

Why AutoNation’s Results Are Bullish for Automakers

June 4, 2012

Our take on AutoNation’s strong sales and Ford’s possible indigenous branding in China.

Bristol-Myers Squibb Cancer Drug Shows Promise

June 4, 2012

Drug maker Bristol-Myers Squibb (BMY) reported some promising results in a Phase-I trial for a cancer drug that helps the body fight cancer cells by harnessing the patient’s immune system.   Link to the trial study results: http://seekingalpha.com/news-article/3046321-investigational-anti-pd-1-immunotherapy-bms-936558-showed-clinical-activity-in-phase-1-trial-of-patients-with-previously-treated-non-small-cell-lung-cancer-metastatic-melanoma-and-renal-cell-cancer   Though the sample size was relatively small, the firm’s study showed that the immune system was more responsive while under drug therapy. Nevertheless, this is the first stage of a very long process to approval, and we aren’t too excited about shares at current levels. We prefer Pfizer (PFE) or Teva Pharmaceuticals (TEVA) at current levels on the basis of our Valuentum Buying Index.   Please click the following link to view our reports on the pharmaceutical industry:   /20110914_1

How Would a Double Dip Impact Retailers?

June 4, 2012

Though we don’t think a double-dip recession in the US is around the corner, we outline our views on how the general economy and employment trends impact same-store-sales performance across the consumer spectrum.

‘The Avengers’ Success Bodes Well for Dividend-Growth Gem Hasbro

May 30, 2012

Dividend-growth portfolio holding Hasbro reported lackluster first-quarter results in April, but the company’s recent success of ‘The Avengers’ could propel earnings in the second and third quarters ahead of consensus estimates. We think Hasbro looks very compelling at current levels.

Monsanto Raises Earnings and Cash-Flow Guidance

May 30, 2012

The world’s largest seed company offered an optimistic outlook for both the remainder of its fiscal 2012 and fiscal 2013. We’ll be taking a look at our fair value estimate for Monsanto and expect to raise it modestly on the news.

RIM Likely to Post First-Quarter Loss, Seeks Strategic Options

May 30, 2012

Research In Motion’s shares look cheap, but its technicals and momentum indicators are atrocious. We’re staying away from this potential value trap.

Revisiting Roundy’s: Dividend Now In Play

May 29, 2012

Roundy’s has declared what seems to be an unsustainable dividend payout, but the firm may still experience significant capital appreciation.

Previous Next

About Our Name

But how, you will ask, does one decide what [stocks are] "attractive"? Most analysts feel they must choose between two approaches customarily thought to be in opposition: "value" and "growth,"...We view that as fuzzy thinking...Growth is always a component of value [and] the very term "value investing" is redundant.

                         -- Warren Buffett, Berkshire Hathaway annual report, 1992

At Valuentum, we take Buffett's thoughts one step further. We think the best opportunities arise from an understanding of a variety of investing disciplines in order to identify the most attractive stocks at any given time. Valuentum therefore analyzes each stock across a wide spectrum of philosophies, from deep value through momentum investing. And a combination of the two approaches found on each side of the spectrum (value/momentum) in a name couldn't be more representative of what our analysts do here; hence, we're called Valuentum.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Valuentum Exclusive publication, ESG Newsletter, and any reports, data and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, data or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor, and does not offer brokerage or investment banking services. The sources of the data used on this website and reports are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum, its employees, and independent contractors may have long, short or derivative positions in the securities mentioned on this website. The High Yield Dividend Newsletter portfolio, ESG Newsletter portfolio, Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Performance, including that in the Valuentum Exclusive publication and additional options commentary feature, is hypothetical and does not represent actual trading. Actual results may differ from simulated information, results, or performance being presented. For more information about Valuentum and the products and services it offers, please contact us at info@valuentum.com.